Oncopeptides has announced that the company has decided to withdraw Pepaxto (INN melphalan flufenamide) from the market in the US, following the phase 3 OCEAN study, which showed an overall survival in the ITT population with a HR of 1.104. The decision has been made after interactions and dialogue with...
Latest News
STAMFORD, Conn. – OncoSynergy, Inc., a physician-founded oncology company committed to advancing therapeutics to address dire unmet medical needs, announced today that the first patient was treated in the Company’s First-in-Human Phase 1 clinical trial evaluating OS2966 for the treatment of recurrent glioblastoma at Moffitt Cancer Center in Tampa, Florida. OS2966...
SAN DIEGO, CA — Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today updated the status of its dose escalation/dose expansion Phase 1/2 Study ONCT-808-101, evaluating the company’s ROR1-targeting autologous CAR T cell therapy ONCT-808 for the treatment of patients with relapsed or...
NEW YORK, NY — OnCusp Therapeutics, Inc., a clinical stage biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients worldwide, today announced that the first patient has been dosed in the Phase 1 study evaluating CUSP06 for the treatment of platinum-refractory/resistant ovarian cancer and...
PARIS — One Biosciences, a biotech company leveraging the power of single-cell analysis and A.I. to identify a new generation of precision medicine targets and treatments, announced today a partnership with Assistance Publique – Hôpitaux de Paris (AP-HP), a consortium of nearly all hospitals in the greater Paris region, to...
ORLANDO, Fla.–The vast majority of advanced colon cancer patients in a clinical trial were not concerned about the cost of prescription drugs for managing chemotherapy side effects, such as infection, pain and nausea and few adopted strategies to reduce drug cost burdens after joining the clinical trial, according to a...
BUFFALO, NY – A new editorial paper was published in Oncotarget’s Volume 14, entitled, “One more step toward treatment of PARP inhibitor-resistant ovarian cancers.” Over 80% of ovarian cancer cases experience recurrence, resulting in roughly 12,000 annual deaths in the United States. While targeted therapies like poly (ADPribose) polymerase inhibitors...
Tel Aviv, Israel – In a first, Tel Aviv University researchers have discovered that the production and regulation of mitochondrial organelles in the brain’s nerve cells (neurons) becomes significantly impaired with the deletion of a gene called Gtf2i, one of the 25 genes deleted in Williams syndrome. This impairment is...
Basel — New results from a one-year Phase III study have confirmed that the investigational biological therapy Ilaris® (canakinumab, formerly ACZ885)[*] produced rapid and sustained remission of symptoms in the majority of children and adults with a rare and potentially life-threatening auto-inflammatory disease called cryopyrin-associated periodic syndrome (CAPS)[1],[2],[3]. The study...
An online symptom management tool that harnesses the problem-solving benefits of expressive writing could help women with ovarian cancer better manage complex symptoms, according to a new study led by a University of Pittsburgh and UPMC nurse-scientist. Published today in the Journal of Clinical Oncology, the study found that patients...